Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Updates from a study evaluating ASTX727 + venetoclax for patients with AML

Tareq Abuasab • 30 Jun 2022
EHA 2022
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes ASTX727 Cedazuridine Decitabine Venetoclax

Tareq Abuasab, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some results from a Phase II study evaluating ASTX727, an orally administered fixed dose combination of decitabine and cedazuridine, plus venetoclax for patients with acute myeloid leukemia (AML) (NCT04746235). Dr Abuasab first discusses the patient population enrolled in this study, and then gives an overview of the overall response rate (ORR) observed and the tolerability of this regimen. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Tareq Abuasab

4:44
Azacitidine + quizartinib for patients with MDS and MPNs with FLT3 or CBL mutation
Tareq Abuasab • 30 Jun 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals